What does Contineum Therapeutics, Inc. do?
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the…
What is Contineum Therapeutics, Inc.'s P/E and P/B ratio?
Contineum Therapeutics, Inc. has a P/E ratio of -4.9 and a P/B ratio of 1.32.
What is Contineum Therapeutics, Inc.'s debt-to-equity ratio?
Contineum Therapeutics, Inc. has a debt-to-equity ratio of 0.03.
How much does Contineum Therapeutics, Inc. owe compared with what it owns?
Contineum Therapeutics, Inc. owes $0.04 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Contineum Therapeutics, Inc.'s Positivity rank?
Contineum Therapeutics, Inc. is ranked #2,992 of 6,767 companies globally and #1,146 of 4,000 in United States on PositoAI, with a Positivity Score of 20,951.
Does Contineum Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Contineum Therapeutics, Inc..
Where can I read the latest news about Contineum Therapeutics, Inc.?
Recent headlines about Contineum Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Contineum Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Contineum Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.